On November 30, 2017, the Company’s shareholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants and directors. On November 29, 2018, the shareholders approved an amendment to the 2017 Plan to add 1.0 to the number of shares of common stock available to grant. As of December 31, 2018, 1.4 shares of common stock were available for issuance. In addition, as of December 31, 2018, the Company may grant additional shares of common stock under the 2017 Plan with respect to the 0.6 options outstanding under its 2003 Plan and 4.1 options and restricted stock units outstanding under its 2010 Plan, that expire or are cancelled without delivery of shares of common stock. At December 31, 2018, 0.4 shares of common stock were available for issuance under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares, which were subject to the RSU, shall again be available for issuance pursuant to the 2017 Plan.

The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs granted to employees generally vest ratably over four years on the anniversary date of the designated day of the last week of the month in which the RSUs are granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and RSUs granted to the Company’s non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant.

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2018 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2018		6.3		$	24.50
Options granted		—		$	—
Less:
Options exercised		(0.7	)	$	24.17
Options canceled or expired		—		$	—
Options outstanding at December 31, 2018		5.6		$	24.54
Options exercisable at December 31, 2018		5.6		$	24.54

As of December 31, 2018, there was no unrecognized share-based compensation expense related to stock options.

A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2018 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2018		2.2		$	31.12
RSUs granted		1.2		$	47.00
Less:
RSUs vested		(0.8	)	$	32.51
RSUs canceled		(0.1	)	$	39.59
RSUs outstanding at December 31, 2018		2.5		$	37.90

As of December 31, 2018, there was $63.3 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.5 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest.

The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of December 31, 2018, approximately 0.6 shares of common stock have been issued under the 2012 Purchase Plan.

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended				Six months ended
	December 31,				December 31,
	2018		2017		2018		2017
Cost of molecular diagnostic testing	$	0.2	$	0.2	$	0.3	$	0.3
Cost of pharmaceutical and clinical services		0.0		—		0.1		0.1
Research and development expense		1.1		1.2		2.3		2.1
Selling, general, and administrative expense		6.2		5.5		12.5		10.8
Total share-based compensation expense	$	7.5	$	6.9	$	15.2	$	13.3